TrialCancer2024

Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.

Anne Knisely et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.